Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Abrams, Jody
VRDN-001-302, NCT06179875: An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies	Recruiting	3	143	Europe, US	Intervention/Treatment	Viridian Therapeutics, Inc.	Thyroid Eye Disease	07/25	03/26
THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )	Active, not recruiting	3	154	Europe, Canada, US, RoW	Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo	Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.	Thyroid Eye Disease	07/24	03/25
THRIVE-2, NCT06021054: An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants with Chronic Thyroid Eye Disease (TED)	Active, not recruiting	3	188	Europe, US, RoW	Veligrotug (VRDN-001), Placebo	Viridian Therapeutics, Inc.	Thyroid Eye Disease	12/24	09/25
Harrison, Andrew
THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )	Active, not recruiting	3	154	Europe, Canada, US, RoW	Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo	Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.	Thyroid Eye Disease	07/24	03/25